A new JAMA Open Network paper concludes that Paxlovid is effective in reducing hospitalizations and deaths in high-risk patients who have been vaccinated or have acquired immunity from previous infections. And a look back at how the drug works its "magic."
Yet another potential Covid treatment has fallen by the wayside. This time it's fluvoxamine, an antidepressant, which showed some promise in minimizing serious disease in small trials. But in a large, randomized trial, it flopped completely. The lesson? You need an antiviral drug to treat a viral infection – not a repurposed drug. These have all failed.
Some doctors are alarmed by the blase attitude toward the Covid drug Paxlovid, quite different from when the drug first became available. What's going on? Some of the waning interest in the drug is because of the widespread use of the term "Paxlovid rebound," implying that there is something wrong with it. More likely, the problem is the term, not the drug.
It's been an interesting month COVID-wise. The COVID antivirals made their way to pharmacies. All in all, things went pretty well (unless you happen to be Merck). Here, you'll learn how to locate pharmacies in your area that have been selected to carry the drugs, and how to see if the pills are in stock.
Finally, there are antiviral drugs that will keep people with COVID out of the hospital (and the morgue). But, good luck getting a prescription if you should need it. The FDA has pretty much guaranteed that this will be almost impossible. Here's why.
The New York Times (correctly) reports that a COVID pill is needed, not just a vaccine. But the paper also tells this story in its typically biased manner, implying that the government, not drug companies, discover drugs. It's a bunch of nonsense that dates back to... forever.
A Medscape article entitled "Five-Day Course of Oral Antiviral Appears to Stop SARS-CoV-2 in Its Tracks" was recently published. Don't fall for the title. It's not that simple.